Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Sanofi SA (NASDAQ:SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5 trial in front-line ER+ metastatic breast cancer in combination with Pfizer Inc's (NYSE:PFE) Ibrance.
- The analyst lowered the price target to $52 and maintained the Outperform rating.
- Related content: Sanofi Ends Development Of Breast Cancer Drug Amcenestrant After Trial Failure.
- SVB previously expected a 2025 launch for amcenestrant and estimated €1.6 billion 2030E sales. Removing amcenestrant did not change 2022-2023E revenue and EPS estimates.
- Though 2025-2031E revenue estimates decreased by 0-3%, EPS estimates decreased by 1-7%.
- The analyst says that after the recent partial clinical hold of tolebrutinib for multiple sclerosis due to liver tox risks, the amcenestrant discontinuation is negative for sentiment for the company's R&D productivity and topline growth prospects.
- Price Action: SNY shares are down 7.10% at $41.63 on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!